Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for ...
Eli Lilly's Q2 revenue surged 36% due to new product launches, but faces supply constraints and a 31% decline in Trulicity revenue. The company's financial health is strong with a 90% increase in operating income, but R&D expenses rose 15%. Eli Lilly's innovative pipeline and strategic acquisitions offer growth opportunities, despite high P/E ratio of 111.1x.
Reference News
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for ...
Eli Lilly's Q2 revenue surged 36% due to new product launches, but faces supply constraints and a 31% decline in Trulicity revenue. The company's financial health is strong with a 90% increase in operating income, but R&D expenses rose 15%. Eli Lilly's innovative pipeline and strategic acquisitions offer growth opportunities, despite high P/E ratio of 111.1x.